drug
donanemab
Marketedupdated 6mo agoby Eli Lilly and Co
Approvedcommunity read0 votes
indications
investigational
Alzheimer's Disease
all catalysts(0)
nothing on the calendar yet
Trials studying donanemab
- phase2A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- —A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
- phase4A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease
- phase3A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
- phase3A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
- phase3Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
- phase2Alzheimer's Tau Platform: Regimen A - AADvac1
- phase2A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
News(10)
- Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.biospace · 1d ago
- London biotech Oyster harvests $60M for tau-targeting brain drugsOyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.biopharma_dive · 7d ago
- Opinion: STAT+: What it’s like to live with cognitively unimpaired Alzheimer’s diseasePeople with cognitively unimpaired Alzheimer’s “may be asymptomatic, but they do have a disease experience,” writes Jason Karlawish.stat · 11d ago
- Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectationsEli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental drug as the Big Pharma expands its neuroscience pipeline through multibilli…fiercebiotech · 19d ago
- Drug prices climb past $250K as US patients balk at the pharmacyJust one-third of patients prescribed new medicines filled them within 30 days, with a new report from the Institute for Clinical and Economic Review and West Health suggesting that cost is the pro…biospace · 26d ago
- Experimental Arrowhead RNAi drug hints at Alzheimer’s benefitIn a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.biopharma_dive · 1mo ago
- Eli Lilly and the LA Dodgers: A tale of 2 dynastiesWatching the baseball playoffs this week, I was struck by the parallels between the Los Angeles Dodgers and Eli Lilly. Both franchises spend a lot of money and always appear to come out on top.biospace · 1mo ago
- Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotechEli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in biobucks per program as part of a collaboration with QurCan Therapeutics.fiercebiotech · 2mo ago
- BMS’ neuro renaissance was built on back of Celgene mega-mergerWell-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological and psychi…biospace · 2mo ago
- Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storeWith so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.biospace · 3mo ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that